Zoledronic acid for congenital dyserythropoietic anemia
Treatments studied
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This trial tests if a bone-strengthening drug called zoledronic acid can help people with congenital dyserythropoietic anemia (CDA), a rare type of anemia. It's for adults with moderate to severe anemia who may also need blood transfusions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of congenital dyserythropoietic anemia (CDA) with a specific gene change (RBM28) or certain bone marrow cell changes.
- Your anemia must be severe enough that you have low red blood cells (hemoglobin below 10 g/dL) or need regular blood transfusions (at least every 8 weeks).
- You need to have good kidney function and normal calcium levels in your blood.
- You must not have gum disease or jaw bone damage, and you must not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks how the body handles a medicine called zoledronic acid in people with kidney disease who are on dialysis and have weak bones (osteoporosis). It may help doctors find the right dose to safely treat bone loss in this group.
This real-world study looks at how the medicine zoledronic acid affects bone-related problems in people with breast cancer that has spread to the bone. It may help reduce events like fractures or other bone complications by protecting bone health.
This trial tests if zoledronic acid, a drug that strengthens bones, can prevent bone loss caused by starting HIV treatment. It is for people newly diagnosed with HIV who have not yet taken any HIV medication.
This trial tests if a bone-strengthening medicine called zoledronate can help prevent bone problems in children and teens who have had a stem cell transplant. It may be an option for patients with low bone density or those who develop graft-versus-host disease after transplant.
This trial tests if zoledronate, a medicine that strengthens bones, can reduce pain in children with CRMO (a condition causing repeated bone inflammation). It compares zoledronate to a placebo (inactive treatment) to see if it helps after 12 weeks.
This trial tests whether adding zoledronic acid (a bone-strengthening medicine) into bone cement at the surgical site can help prevent giant cell bone tumor from coming back after surgeons scrape it out from inside the bone. It is for people whose tumor can be treated with a specific “scrape-and-reconstruct” surgery and who have not had related medicines before.
Hear when a new Congenital Dyserythropoietic Anemia (CDA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.